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Misfolding of DF508 cystic fibrosis (CF) transmem-
brane conductance regulator (CFTR) underlies pa-
thology in most CF patients. F508 resides in the first
nucleotide-binding domain (NBD1) of CFTR near
a predicted interface with the fourth intracellular
loop (ICL4). Efforts to identify small molecules
that restore function by correcting the folding
defect have revealed an apparent efficacy ceiling.
To understand the mechanistic basis of this ob-
stacle, positions statistically coupled to 508, in
evolved sequences, were identified and assessed
for their impact on both NBD1 and CFTR folding.
The results indicate that both NBD1 folding and inter-
action with ICL4 are altered by the DF508 mutation
and that correction of either individual process is
only partially effective. By contrast, combination of
mutations that counteract both defects restores
DF508 maturation and function to wild-type levels.
These results provide a mechanistic rationale for
the limited efficacy of extant corrector compounds
and suggest approaches for identifying compounds
that correct both defective steps.
INTRODUCTION
Cystic fibrosis (CF) is a lethal, monogenic disease caused by
dysfunction of the CF transmembrane conductance regulator
(CFTR). CFTR is a member of the ATP-binding cassette (ABC)
transporter family that functions as a chloride channel. The
protein is composed of five domains: two transmembrane
domains (TMDs) that form the channel through the membrane,
two nucleotide-binding domains (NBDs) that gate the channel
through ATP-binding and hydrolysis reactions, and a regulatory
region (R) that mediates kinase-dependent regulation of activity164 Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc.(Figures 1A and 1B) (Berger et al., 2005; McCarty, 2000; Men-
doza and Thomas, 2007; Riordan et al., 1989; Vergani et al.,
2005). Most commonly, CF is associated with the deletion of
a single amino acid, Phe508, in the first NBD (NBD1) of CFTR
(Figures 1A–1C) (Riordan et al., 1989). DF508 CFTR fails to fold
properly and does not efficiently traffic to the plasma membrane
(Cheng et al., 1990) resulting in a loss-of-function (Rich et al.,
1990). The mutant CFTR is active when induced to fold and
traffic to the membrane (Denning et al., 1992; Teem et al.,
1993), indicating that compounds that correct the folding defect
may have therapeutic benefit.
Studies of theNBD1ofCFTR indicate that the deletion reduces
folding efficiency (Qu and Thomas, 1996; Thibodeau et al., 2005)
and stability (Hoelen et al., 2010; Protasevich et al., 2010; Thibo-
deau et al., 2010; Thomas et al., 1992; Wang et al., 2010). Crystal
structures of the isolated CFTR-NBD1 domains reveal that F508
is partially exposed on the surface (Lewis et al., 2004) and
that deletion of the residue causes only local rearrangements in
the loop following the 508 residue in the context of stabilizing
mutations that facilitated crystallization (Atwell et al., 2010; Lewis
et al., 2005).
Evidence suggests that DF508 CFTR can be targeted to
improve folding and restore function. A patient with a less severe
form of CF had DF508-R553Q on one allele and a nonsense
mutation on the other (Do¨rk et al., 1991). Amating screen in yeast
utilizing a CFTR-Ste6 chimera identified the same R553Q muta-
tion as a suppressor of the loss-of-mating DF508 phenotype
(Teem et al., 1993). Additional second-site revertant mutations
I539T, G550E, R553M, and R555K, within the portion of CFTR
NBD1 included in the chimera, were also identified (DeCarvalho
et al., 2002; Teem et al., 1993, 1996). The R553M, I539T, and the
combination of G550E-R553M-R555K (3M) mutations correct
the folding and stability defects of the DF508 NBD1 domain in
isolation (DeCarvalho et al., 2002; Hoelen et al., 2010; Pissarra
et al., 2008; Qu et al., 1997; Thibodeau et al., 2010) but only
partially restore maturation of the full-length mutant protein
(Hoelen et al., 2010; Pissarra et al., 2008; Thibodeau et al.,
2010). These data indicate that correction of the NBD1 folding
Figure 1. Relationship of CFTR Domains to the F508 Position
(A) CFTR is 1,480 amino acids in length and contains two transmembrane
domains (TMDs, orange and pink) and four intracellular loops (labeled ICL1-4,
cyan, orange, blue, and yellow), two nucleotide-binding domains (NBDs, gray
and charcoal), and a highly disordered Regulatory region (R, purple). F508,
green is located within the NBD1 domain.
(B) The Sav1866 based homology model of CFTR sans R region (PDBs 2HYD,
1R0W, and 3GD7). Top: view of the NBDs and ICLs of CFTR parallel to the
membrane. The two NBDs associate in a head-to-tail fashion. ICL1 (cyan
ribbon) and ICL4 (yellow ribbon) interact with NBD1 and ICL2 (orange ribbon)
and ICL3 (blue ribbon) interact with NBD2. F508 (green surface) is at the
predicted interface with ICL4. NBD1 surface residues predicted to be within
6 A˚ of ICL1, ICL4 or both are highlighted in cyan, yellow, or light green
respectively. Bottom: view of the CFTR model looking down from the
membrane (90 relative to top). See also Figure S1.
(C) Ribbon representation of NBD1 (PDB 1R0W) showing relationship of F508
(green sticks) to the predicted interface with ICL4 yellow outline.defect alone only incompletely restores maturation of DF508
CFTR.
Based on the hypothesis that compounds that effectively
improve the folding of DF508 CFTR would be of therapeutic
benefit, several cell-based high-throughput screens have been
performed (Pedemonte et al., 2005; Robert et al., 2008, 2010;
Van Goor et al., 2006). Although some of the compounds identi-
fied bind to and stabilize NBD1 (Sampson et al., 2011), the
mechanism of action of most remains unknown. None of the
reported DF508 correctors have potency much less than 1 mM
and, like the single intragenic second site-suppressor mutants,
efficacy above 15% of wild-type levels (Van Goor et al.,
2011). There is reasonable concern that this degree of correction
will not provide therapeutic benefit based on the promising
results with the more potent and efficacious potentiator of the
rarer CF-causing G551D gating mutant (Accurso et al., 2010;
Van Goor et al., 2009). This potentiator compound, VX-770,
demonstrates that pharmacological improvement of mutant
CFTR function in adult patients provides a measurable clinical
benefit (Accurso et al., 2010), further stimulating the search for
effective correctors of DF508 folding and function. Under-
standing the molecular basis of the apparent correction ceiling
and the mechanism of action of corrector compounds would
provide critical insight for development of corrector compounds.The identification of positions coupled to F508, provided by
the Ste6-CFTR chimera revertant mating screen, has provided
insights into CFTR folding and the effect of DF508 but was
limited to residues immediately proximal to the F508 position
(Teem et al., 1993, 1996). Extending such a second-site analysis
to the whole of CFTRmight be expected to provide new informa-
tion about the folding and maturation of CFTR and the effect of
the DF508 mutation thereon—information critical for revealing
the mechanism of action of extant correctors, for developing
methods capable of identifying better compounds, and for
a fundamental understanding of the process of membrane
protein folding. In the absence of a conveniently assessed
phenotype for CFTR function as required to evaluate millions of
individual genetic perturbations, the information nature has
provided in the sequences of the ABC supergene family offer
an alternative. Multiple algorithms have been developed that
can identify residues coupled to specific positions, for example
F508, in the evolved sequences of protein homologs (Fodor
and Aldrich, 2004; Goh et al., 2000; Kass and Horovitz, 2002;
Lockless and Ranganathan, 1999; Pazos and Valencia, 2008;
Socolich et al., 2005). The set of residues statistically coupled
to the F508 position would be expected to be enriched for posi-
tions that interact directly or allosterically in the final structures or
transiently during the process of folding. Such interactions
should be evident in the stability and folding yield of NBD1 and
the maturation of CFTR, which reflects the association of folded
NBD1 with ICL4. In the present work we identified positions
coupled to F508 in CFTR and determined their effect on both
NBD1 folding and CFTRmaturation. The results reveal the quan-
titative effect of the DF508 mutation on two distinct steps of
folding and, further, suggest mechanistically defined methodol-
ogies for identifying compounds targeting either or both steps
defective in the mutant protein.
RESULTS
Positions Coupled to 508 in the ABC Transporter
Supergene Family
CFTR is a member of the ABC transporter supergene family
(Dean and Annilo, 2005). Over 2,000 full-length sequences of
eukaryotic ABC transporters (containing two NBDs and two
TMDs on a single polypeptide) were obtained from iterations of
a PSI-Blast default search using the human CFTR protein
sequence as the seed (gi 90421313). Four multiple sequence
alignments (MSA) were generated using ClustalW (Larkin et al.,
2007). After quality assessment using the three highly conserved
Walker A and B, and consensus motifs (Dean and Allikmets,
1995; Dean and Annilo, 2005; Jones and George, 2004; Walker
et al., 1982), the sequences to be queried was reduced by half.
Removal of additional sequences that had >90% identity to
any other sequence, produced a set of 493 full-length sequences
(MSA available for download at http://cftrfolding.org). The NBD
domains have the highest number of conserved positions in
the MSA. Four positions in CFTR are invariant in the alignment,
K464 and G1244 in the Walker A motifs of NBD1 and NBD2,
respectively, Q1292, the Q loop residue in NBD2, and D1370
of the NBD2 Walker B motif. The TMDs have high conservation
at or near the ICLs. The scores in the R domain approachCell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc. 165
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Figure 2. CFTR Inter-Residue Coupling
Matrix Calculated from an ABC Transporter
Sequence Alignment
(A) Left: heat map of the 1,480 3 1,480 matrix
representing a linear combination of statistical
methods (SCA, ELSC,OMES,McBASC). The color
scale (right) with statistical scores approaching
zero represented by dark blue and scores of high
statistical significance in red. The diagonal
denotes identity. Coupling of each of the five
domains of CFTR to NBD1 are shown in squares
with TMD1 in orange, NBD1 coupling to itself in
light gray, the R region in purple, TMD2 in pink, and
NBD2 in dark gray. See also Figure S2. Right: the
285 3 285 matrix of coupling scores within NBD1
(positions 389–673 of the left panel). Above the
matrix is the column of coupling scores for every
position in NBD1 to the 508 position. The con-
served Walker A and B, consensus motifs, and the
508 position are denoted by arrows.
(B) Left: the 508-coupling scores in ICL1 (residues
158–184) and ICL4 (residues 1050–1080) of the
CFTR model (Figure 1B). The surface corre-
sponding to the F508 position is colored in green
and is predicted to be in contact with ICL4. Right:
view of NBD1 (PDB 1R0W) colored with normal-
ized scores from (A). The F508 position is shown in
green.randomness (conservation score of 1). Phe is the most
common amino acid at the 508 position followed by Tyr at
frequencies of 0.86 and 0.11, respectively.
Matrices of the pairwise correlation scores were calculated
using the MSA by four independent, statistical methods, statis-
tical coupling analysis (SCA), explicit likelihood of covariation
(ELSC), OMES, and McBASC (Figures 2A and 2B; Figure S2
available online) (CSV files are available for download at http://
cftrfolding.org) (Dekker et al., 2004; Fodor and Aldrich, 2004;
Lockless and Ranganathan, 1999). The top 20 statistical
508-coupled positions for the four methods formed a set of 45
positions (Table 1). A random set of 16 of these 45 508-coupled
positions (Table 1; Figure S3), were assessed for effects onCFTR
folding. The 16 positions represent 78% coverage of the top
ten 508-coupled positions for all four methods and include six
positions common between all four methods, two positions
between three methods, six positions between two methods,
and two positions unique to a single method (Table 1). The six
coupled positions common between all four methods are
located in the a-helical subdomain (Table 1; Figure S3). Ten of
the sixteen positions are surface exposed; F490L and W496,
like F508, are predicted to be at the ICL4 interface (Table 1; Fig-
ure S3). Additional positions reside within the coupling helix
boundaries of ICL1 and ICL4 (Figure 2B). Each of the 16 positions
in CFTR was mutated to the most common non-CFTR amino
acid (Table 1), and the effect on both NBD1 folding and CFTR
maturation was assessed.
Mutations at 508-Coupled Positions Affect NBD1
Folding
The 16 508-coupled positions and previously identified second-
site suppressor mutations, and combinations thereof, were166 Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc.evaluated for effects on the folding of the isolated human
CFTR NBD1 using a structural complementation assay previ-
ously described (Thibodeau et al., 2010; Wigley et al., 2001).
In the current implementation of the assay, the folding signal
of DF508 NBD1 was 0.43 ± 0.03 relative to wild-type NBD1,
1.00 ± 0.03. All 16 508-coupled and second-site suppressor
mutations had a significant effect on the folding of the isolated
domain relative to wild-type (Figure 3A), suggesting that the
statistical analyses identified a set enriched for biological rele-
vance. Fourteen of the 508-coupled mutations interfered with
NBD1 folding (Figure 3A, green bars). The significance of the
decrease in folding was <6E6 for 13 of the mutants and
0.002 for the least significant, E583G. Two 508-coupled
mutants, D529F and S573E, dramatically increased the relative
folding yield of NBD1 by 3.07- ± 0.13-fold and 1.85- ± 0.06-
fold, respectively, a level comparable to that of the second-
site suppressors identified in the STE6 chimera screen
(Figure 3A).
Thermal denaturation of purified D529F and S573E NBD1
revealed that S573E raised the Tm by 2
C–5C relative to wild-
type depending on ATP concentration (Figure S4B), indicating
the improved folding yield in the complementation assay could
be accounted for by increased stability of the native state (Fig-
ure 3B). In stark contrast, D529F had no measurable effect on
Tm indicating the complementation assay reflects changes in
yield and pathway as well as changes in stability or solubility.
D529 is located in the a-helical subdomain of NBD1 near the
NBD1-NBD2 interface (Figure 1C). Analysis of the human
NBD1 crystal structures (PDB 2BBO and 1XMI) reveals this as-
partic acid side chain forms a salt bridge with R555. The R555
side chain also makes a hydrogen bond with the backbone
carbonyl of Q525 (Figure S4A). The R555K missense mutation
Table 1. Top 20 508-Coupled Positions within NBD1 Using Four
Independent Statistical Methods
ELSC McBASC OMES SCA
435
453
460
S466T S466T
468
470
472
473 473
474 474
L475Y L475Y L475Y
F490L F490L
W496V W496V W496V W496V
503
505
507
509
512
513
Y517I Y517I Y517I Y517I
520 520
521
C524A C524A C524A C524A
L526A L526A L526A L526A
D529F D529F D529F D529F
D537F D537F
543
Y563V Y563V Y563V Y563V
A566P A566P
569 569
S573E
P574A P574A P574A
F575T F575T
578
582
E583G E583G
587
591
595
598
602
604 604 604
H609T
617
630 630
640
The alignment of 493 sequences was used to calculate pairwise coupling
scores using each method (ELSC, SCA, McBASC, and OMES). The top
20 are shown for each method, the top 10 positions in bold. The tested
set of 16 positions are underlined. See also Figure S3.is one of the previously studied second-site suppressors of
DF508 NBD1 mediated misfolding (Roxo-Rosa et al., 2006;
Teem et al., 1996). R555K increased the folding yield of NBD1,
3.26- ± 0.07-fold over wild-type (Figure 3A). The Tm of R555K
NBD1 was 6.4C higher than wild-type in 2 mM ATP. A Glu or
Asp at the CFTR equivalent 573 position is the catalytic base in
the highly conserved Walker B motif in other ABC transporters
(Jones and George, 2004; Mendoza and Thomas, 2007; Walker
et al., 1982). The serine present in CFTR at this position accounts
for the lack of ATP hydrolysis at this site as central to the mech-
anochemistry of the gating cycle (Figure S4B) (Vergani et al.,
2003).
Mutations at 508-Coupled Positions Affect Maturation
To examine the relationship of NBD1 folding and stability with
full-length CFTR folding, mutant CFTRs were expressed in
HeLa cells, and CFTR maturation was determined by two
methods. As CFTR folds, it traffics from the ER to the Golgi
where it attains complex glycosylation prior to reaching the
plasma membrane. The resulting increase in molecular mass
can be detected by western blotting of SDS-PAGE (Figure 4).
The slower migrating complex glycosylated Band C reflects
the folded, mature CFTR whereas the more rapidly migrating
Band B reflects core glycosylated CFTR that has not reached
the Golgi (Cheng et al., 1990). These data have been utilized
in several ways to monitor the effect of mutations and
compounds on CFTR folding. The ratio of Band C to Band B
is linear with both CFTR at the surface as monitored by bio-
tinylation and with Band C itself (Figure S5C). By contrast the
ratio of Band C over total CFTR has a nonlinear relationship
with mature surface CFTR, being more sensitive to changes at
low folding yields (Figure S5B). In these analyses it was noted
that none of the mutants tested had a significant effect on the
amount of Band B and thus, the total CFTR was linear with
the amount at the surface (Figure S5C). An ELISA assay for total
CFTR quantitation was developed and used to monitor CFTR
maturation. The signal from this method is not only linear but
has lower noise than other methods (Figure S5C). The influence
of all the 508-coupled mutants on CFTR folding was assessed
(Figure 4A). All 16 of the 508-coupled mutations and second-
site suppressor mutations altered the yield of full-length CFTR
relative to wild-type. The same 14 mutations that reduced the
yield of NBD1 folding, reduced maturation of full-length CFTR
(Figure 4A, green bars). The p value for all is <0.04. The same
two mutations that improved NBD1 folding yield, D529F and
S573E, increased the maturation efficiency of CFTR (Figure 4A,
yellow and magenta bars, respectively). The previously identi-
fied second-site suppressor mutants also improved CFTR
maturation in a manner consistent with their effects on NBD1
folding. The correlation between NBD1 folding and CFTR matu-
ration is formalized in Figure 4B. The data indicate a linear
relationship (R = 0.85) with a slope of 0.75. Thus, NBD1 folding
is necessary for CFTR folding and for every fold change in NBD1
yield a concomitant change of 0.75 in CFTR yield is observed.
The position along the x axis thus reflects the amount of folded
NBD1 and the slope of the line likely reflects later steps in
folding during which folded NBD1 associates with other parts
of CFTR.Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc. 167
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Figure 3. Effects of 508-Coupled Mutations
and Second-Site Suppressors on NBD1
Folding
(A) The relative yield of NBD1 folding was deter-
mined using a cell-based assay. All mutations
altered the relative yield relative to wild-type NBD1
as shown in the bar chart (± standard error of the
mean [SEM], n = 9 except for WT, DF508, D529F,
and S573E where n = 18). Two of the 508-coupled
positions, D529F and S573E, increase the yield of
NBD1. The remainingmutations decrease the yield
of soluble NBD1.
(B) Thermal denaturation of 5 mM purified recom-
binant WT, D529F, and S573E NBD1 in the pres-
ence of 2 mM ATP (left panel). See also Figure S4.
By contrast to the increased NBD1 folding yield,
the D529F mutation (yellow circles) has no
observable effect on thermal stability relative to
WT (black circles). S573E (magenta circles) in-
creased the melting temperature 2C. Correlation
between thermal stability of bacterially expressed
and purified NBD1 and NBD1 folding yield (right
panel). For mutants on either WT (circles) or DF
(triangles) backgrounds, the correlation between
stability and folding yield, R = 0.94 when D529F is
excluded (yellow circle) (right panel, ±SEM).Influence of DF508 on NBD1 Folding and Later Steps
in CFTR Maturation
To determine whether in addition to its known effects on NBD1
folding and stability, DF508 interferes with later steps in CFTR
folding, the differential effects of the NBD1 suppressormutations
on the wild-type and DF508 NBD1 folding yield and CFTR matu-
ration yield were measured and correlated (Figure 5B). Interest-
ingly, the two suppressors identified by the coupling analysis,
D529F and S573E, had much more modest effects on NBD1
yield in the presence of the DF508 mutant as might be expected.
Taken together, the suppressors define a line (m = 0.10, R = 0.36)
in the context of DF508, indicating that the mutation interferes
with a later step in CFTR folding in addition to its defect in
NBD1 folding yield. Thus, the mutation decreases NBD1 folding
yield 3-fold and later CFTR folding steps by 7-fold.
Extant structures of CFTR DF508 NBD1 contain a series of
previously identified second-site mutations that improve folding
and solubility of the model domain. To simplify structural inter-
pretation of the current results, a high resolution structure of
murine DF508 NBD1 without additional mutations or deletions
was solved (Table S1). Comparison of the backbones of the
murine wild-type (PDB 1R0W) and DF508 NBD1 (PDB 3SI7)
structures reveal nearly identical structures, root-mean-square
(rms) 0.249 A˚, with backbone shifts immediately following the
508 position. The largest shift in Ca between the two structures
is G509 shifting by 3.5 A˚ followed by a 1.5 A˚ shift for V510 before
theDF508 backbone converges with wild-type. The surface view168 Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc.of the two structures suggests local
changes near the site of the deletion (Fig-
ure S1) similar to the structures contain-
ing the second-site mutations (Lewis
et al., 2010, 2005). The absence of theF508 side chain creates a significant pocket on the surface of
NBD1 at the predicted interface between ICL4 and NBD1 (Fig-
ure S1B). Additionally, the V510 side chain rotates outwardly
3.6 A˚ (Cb) from the core in themutant structure, further increasing
the size of the pocket.
To better understand the molecular basis of the later step in
folding effected by the DF508 mutation, we built upon earlier
work indicating that mostmissensemutations at the 508 position
do not have dramatic effects on NBD1 but rather interfere with
CFTR maturation (Du et al., 2005; Thibodeau et al., 2005). The
current assay battery was applied to a set of these mutations
alone or in combination with the NBD1 suppressors (Figure 5C).
When F508 is replaced by Lys, very little CFTR maturation is
observed regardless of the ability of the NBD1 to fold (m =
0.03, R = 0.38). The model of CFTR (Mendoza and Thomas,
2007) based on alignment with Sav1866 (Dawson and Locher,
2007) places F508 (or the DF508 pocket) near R1070 in ICL4
(I218 in ICL2 of Sav1866) (Figure 5C, top). Residues in ICL4
coupled to the 508 position exhibit a helical pattern consistent
with the structural model. To assess the NBD1-ICL4 interface
from the ICL4 side of the interface, a large tryptophan side chain
replaced the native arginine. The R1070W sterically clashes with
the F508 position in the model (Figure 6A, top) a prediction
consistent with fact that it is a CF-causing mutation (Krasnov
et al., 2008) that inhibits CFTR maturation when F508 is present
(open circle, Figure 6A, bottom). By contrast, the introduction of
the larger side chain at 1070 is accommodated by the DF508
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Figure 4. Effects of 508-Coupled and Second-Site Suppressor
Mutations on CFTRMaturation: Correlation with NBD1 Folding Yield
Effects of 508-coupled mutations (green, yellow, and magenta) and second-
site suppressors (orange) on thematuration of full-length CFTR and correlation
with NBD1 folding yield.
(A) The efficiency of full-length CFTR maturation was determined by ELISA
(±SEM, n = 6 for WT, DF508, D529F, and S573E, n = 3 for other mutants).
A control western blot is shown above the bar graph. All mutations altered
maturation relative to wild-type CFTR. The two 508-coupled positions that
increased NBD1 folding yield, D529F and S573E, also increased the matura-
tion yield of CFTR (yellow andmagenta bars, respectively). See also Figure S5.
(B) The influence of the 508-coupled mutations (green circles), four second-
site suppressor mutations (I539T, G550E, R553M, and R555K) and three
suppressors in combination (G550E, R553M, and R555K) (orange circles) on
F508 background on relative maturation of full-length CFTR and relative NBD1
folding yield is correlated (green line, m = 0.75, R = 0.85). The two F508-
coupled position mutations, D529F and S573E, are colored in yellow and
magenta circles, respectively.pocket in the mutant NBD1, and, could allow for better packing
(Figure 6B, top) that promotes folding (open triangle, Figure 6A,
bottom) by correcting the ICL4-DF508-NBD1 interface defect.
The ability of the R1070W mutation to counteract the ICL4-
NBD1 interface defect caused by the DF508 mutation, allowed
assessment of the quantitative effects of suppression of both
defects concurrently. When NBD1 suppressor mutations were
introduced on top of R1070W andDF508, the slopewas restored
(m = 0.77, R = 0.47) (Figure 6B). Thus, correction of the two
defects results in near total rescue of the mutant folding pheno-
type. A 3-fold improvement in DF508 NBD1 folding yield, cor-
recting the NBD1 to wild-type levels, results in a modest
improvement in CFTR maturation (0.10 slope). Similarly, the
R1070W interface mutant produces an 7-fold increase in the
slope, but only a modest improvement in CFTR maturation.
However, when the two effects are combined, they have a
multiplicative effect on folding.
CF is a loss-of-function disease. To determine whether effi-
cient correction of maturation was adequate to restore function,
CFTR activity was measured for mutations that corrected either
the NBD1 defect or the ICL4-NBD1 defect or both. Two assays
were employed: transepithelial ion conductancewas determined
in FRT cell monolayers (Figure 6C) and whole-cell currents were
measured in HeLa cells (Figure 6D). CFTR dependent function
was taken as the forskolin dependent, Inh-172 sensitive activity.
Mirroring the maturation results, correction of either the NBD1
defect (I539T, R555K, red bars) or the ICL4-NBD1 defect
(R1070W, white bar) alone provided only modest improvements
of function. Like maturation, combination of the two types of
correction mutations (cyan bars) had a synergistic effect,
restoring CFTR function to near wild-type levels.
DISCUSSION
The most common CF-causing mutation, DF508, disrupts the
normal folding pathway of CFTR leading to the loss-of-function
that underlies pathogenesis (Cheng et al., 1990). The mutant
protein is active when induced to fold (Denning et al., 1992;
Teem et al., 1993) suggesting a novel pharmacological approach
to treating CF. Small molecules that bind to and counteract the
folding DF508 defect would provide a means of repairing the
protein (Thomas et al., 1992) while maintaining normal regulation
and expression patterns. Multiple efforts to identify such com-
pounds have been reported (Pedemonte et al., 2005; Robert
et al., 2010, 2008; Sampson et al., 2011; Van Goor et al.,
2006), but the identified molecules are not very potent and
correct mutant CFTR folding to no more than 15% of wild-type
(Van Goor et al., 2011). Understanding the basis of this observed
efficacy ceiling would provide information critical for determining
the feasibility of the corrector approach and guide any future
discovery efforts. Although it is known that CFTR folding is a
hierarchical process that occurs partially during translation (Du
et al., 2005; Hoelen et al., 2010; Thibodeau et al., 2005) and
that the DF508 mutation interferes with NBD1 folding (Hoelen
et al., 2010; Protasevich et al., 2010; Thibodeau et al., 2005;
Thomas et al., 1992) and is reflected in other domains (Du
et al., 2005), fundamental details of the folding pathway and its
disruption are lacking.Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc. 169
Figure 5. DF508 and 508MissenseMutations Influ-
ence the Correlation of CFTR Maturation with
NBD1 Folding Yield
(A) View of the CFTR NBD1-ICL1/4 interface, as described
in Figure 1B.
(B) Deletion of the F508 residue creates a pocket on the
NBD1 surface near the predicted ICL4 interface (compare
DF508 model built with PDB 3SI7, to wild-type Figure 1C,
PDB 1R0W). See also Table S1. Previously identified
second-site suppressor (I539T, G550E, R553M, R555K,
and 3M) but not the 508-coupled mutants (D529F and
S573E) increase the yield of DF508 NBD1. The correlation
between increased NBD1 yield and relative yield of
DF508 CFTR is shallower (red line, m = 0.10, R = 0.36) than
wild-type (green line, m = 0.75, R = 0.85) (±SEM). See also
Table S2.
(C) F508K, F508R, and F508K in combination with I539T,
G550E, R553M, R555K, and 3M mutations increase
folding yield of NBD1, but exhibit no corresponding
increase in CFTR maturation yield (dark blue circles and
line, m = 0.03, R = 0.40) (±SEM, n = 9 along x axis and n = 3
along y axis).To gain insight, we identified residues coupled to the 508 posi-
tion utilizing a computational approach. Several methods have
been developed to use evolutionary sequence analysis to iden-
tify networks of residues within proteins important for function,
to improve native intermolecular contact prediction algorithms,
and to identify hot spots of ligand binding or protein-protein
interactions (Dekker et al., 2004; Goh et al., 2000; Lockless
and Ranganathan, 1999; Madaoui and Guerois, 2008; Pazos
and Valencia, 2008; Socolich et al., 2005). We used the ABC
transporter family to identify positions related to F508 and its
important role in folding. Multiple evolutionary coupling algo-
rithms were utilized to identify relevant positions. Remarkably,
the 16 508-coupled mutants selected and tested all effect the
folding of both the isolated domain and the full-length CFTR.
Fourteen mutations made folding worse and two improved the
folding. These results are not likely to occur by random chance.
For example, two randommutant screens found 0.03%of clones
in the library improved folding, whereas 20% of mutants mis-
folded with an average of two mutations per clone, demon-170 Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc.strating the inherent mutational robustness of
proteins (Kunichika et al., 2002; Pjura et al.,
1993) and the utility of the computational
methods. In comparison to the random screens,
we were 400 times more likely to identify muta-
tions that improve folding and four times more
likely to identify mutations that result in
misfolding.
Identified in this study, D529F and S573E
improve folding of NBD1 in isolation and matu-
ration of full-length CFTR in the wild-type
background. The human CFTR 573 position
corresponds to a highly conserved Glu, the
catalytic base, of the Walker B motif in other
members of the ABC transporter family and in
the second NBD of CFTR (Walker et al., 1982).
However, CFTR proteins have a serine at thisposition, accounting for the lack of ATPase activity at this site.
Reversion to Glu does not restore catalytic activity at this site
indicating there are other changes important in the evolution of
CFTR as a channel from a family of transporters (Stratford
et al., 2007; Vergani et al., 2003). In this work, we found the
wild-type protein is less stable than the mutant containing the
conserved residue (Figure 3B, leftmost panel; Figure S4B).
Analyses of identified coupled positions in the wild-type and
DF508 backgrounds, utilizing methodologies to facilitate the
large number of samples, demonstrated that there are two steps
in CFTR folding in which DF508 is defective, NBD1 folding and
a later step involving NBD1 and ICL4. The correction of only
one defect by suppressor mutations or compounds has limited
efficacy as is reflected in the partial maturation and function of
DF508 CFTR to <20% of wild-type, the previously observed
‘‘ceiling.’’ In plots of CFTR folding yield against NBD1 folding
yield, the position along the x axis reflects the first step in folding
and the slope of the line reflects the later steps including the
NBD1-ICL4 interface.
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Figure 6. Correction of the DF508 NBD1-
ICL4 Interface Defect Is Synergistic with
Correction of the DF508 NBD1 Folding Yield
Defect
(A) CFTR maturation yield as a function of NBD1
folding yield for wild-type, DF508, and the ICL4-
NBD1 interface mutants are shown as green, red,
and dark blue lines for comparison. The R1070W
(open triangle) mutation in ICL4 modestly
improves the relative yield of DF508 CFTR matu-
ration and decreases the relative yield for CFTR
wild-type (open circle) consistent with the pre-
dicted steric clash with the F508 side chain (top)
(±SEM). See also Table S2.
(B) Top: by contrast, in the model Trp is accom-
modated by the pocket formed by the DF508
mutant (PDB 3SI7) See also Table S1. When
R1070W is combined with mutations that improve
DF508 NBD1 folding yield, I539T, G550E, R553M,
R555K, and 3M (open triangles), the correlation
between NBD1 folding and CFTRmaturation in the
wild-type protein is restored (m = 0.77, R = 0.47,
black line) (±SEM). See also Table S2.
(C) CFTR-dependent transepithelial conductance.
Monolayers of FRT cells transiently expressing
CFTR were stimulated with 10 mM Forskolin +
100 mM IBMX and transepithelial conductance
measured (top, ±SEM, n = 3, average con-
ductance for wild-type = 1.24 mS). The CFTR
dependence of conductance is indicated by the
sensitivity to 20 mM Inh-172 (bottom). See also
Table S2.
(D) Forskolin stimulated, Inh-172 sensitive whole-
cell currents of HeLa cells transiently expressing
CFTR reveal a correlation between current density
after activation (10mMforskolin+100mMIBMX)with
relative yieldofCFTR (black line,±SEM,n=5–6) and
in the presence of Inh-172 (10 mM) dotted line
(±SEM, n = 4–6). A representative trace of the cor-
rected mutant, DF508-I539T-R1070W CFTR (cyan
triangles) is more like wild-type (filled circles) than
DF508 (filled triangles) (inset). See also Table S2.The experiments with the second-site suppressor mutations
on the F508K background demonstrate, regardless of how
well NBD1 folds, CFTR is unable to mature if the NBD1-ICL4
is disrupted. Likewise, CFTR cannot mature if NBD1 is unable
to form a native structure. These findings predict that screens
for compounds that improve CFTR maturation or function might
be biased against compounds that act specifically against
either individual folding defect as they would produce improved
position on the x axis or a steeper slope but little actual
improvement of CFTR maturation and function. Unless single
compounds can correct both steps, the set of highest hits in
such screens are likely to be populated with compounds that
do not directly act on CFTR. Thus, these findings have implica-
tions for the discovery and development of CF therapeutics.
Compounds, or combinations of compounds, that correct
both defective steps could provide both on target specificity
and efficacy of action. The assay systems and second-site
mutants developed may also find utility in establishing a mech-
anism of action of extant correctors and aid in the identification
of new compounds.EXPERIMENTAL PROCEDURES
Bioinformatics
The human CFTR sequence (gij90421313) was used as a seed for PSI-Blast
(Altschul et al., 1997) of the nonredundant database. Subalignments were per-
formed using ClustalW and assessed (Larkin et al., 2007). Sequences lacking
conserved ABC transporter motifs (Walker A, B, and/or consensus motifs)
(Walker et al., 1982) were removed. The final alignment was generated online
using Promals 3D (Pei et al., 2008a, 2008b). Proteins >90% identity to any
other protein in the alignment were removed. The alignment contains 493
sequences. Positional entropy based conservation scores were calculated
using AL2CO (Pei and Grishin, 2001) and frequencies of the most common
amino acid position identified and calculated via Perl scripting.
The multiple sequence alignment was used to calculate pairwise correlation
matrices using SCA (Lockless and Ranganathan, 1999), ELSC (Dekker et al.,
2004), OMES (Kass and Horovitz, 2002; Larson et al., 2000; Fodor and Aldrich,
2004), and McBASC (Go¨bel et al., 1994; Olmea et al., 1999). Pairwise correla-
tion scores for SCA were calculated in MATLAB (The MathWorks) using the
algorithm provided by Lockless and Ranganathan (1999). ELSC, OMES, and
McBASC scores were calculated using the downloaded package from A. Fo-
dor (http://afodor.net). Mutations at each of the positions were selected
utilizing amino acid distribution profiles complementing correlated changes
at the 508 position.Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc. 171
NBD1 Folding Yield
pcDNA 3.1(+) constructs containing human WT and DF508 CFTR NBD1 (resi-
dues 389–673) were used as previously described (Thibodeau et al., 2010;
Wigley et al., 2001). HeLa TetOn (Clontech Laboratories) cells were transiently
transfected using Lipofectamine 2000 (Invitrogen) at a cell density of 320,000
cells/ml. After transfection, cells were grown at 37C for 18–24 hr. Media was
aspirated from eachwell and 50 l of 2.5 mMfluorescein-di-b-D-galactopyrano-
side (FDG) (Sigma-Aldrich) substrate in Reporter lysis buffer (Promega) added.
Fluorescence was measured every minute for 24 hr. Rates were determined
from the linear portions of the data. p values were determined using the
Student’s t test with a two-tail distribution of a two-sample heteroscedastic
test.
CFTR Maturation Yield
With pCMV-CFTR (a gift from J. Rommens) HeLa TetOn (Clontech) cells were
transiently transfectedwith Lipofectamine 2000 (Invitrogen) and grown at 37C
for 24 hr. Effects of mutations on maturation of CFTR was visualized by
western blot analysis and quantitated by a sandwich ELISA utilizing mAb
A596 (J. Riordan, UNC) as the capture antibody and 3G11 (W. Balch, Scripps)
as the detection antibody. Characterization of the ELISA maturation assay and
detailed methods are included in the Extended Experimental Procedures and
Figure S5.
Protein Expression, Purification, and Characterization
Murine DF508 NBD1, 389–673 human numbering, was expressed and puri-
fied as previously described except bacterial pellets were not frozen (Lewis
et al., 2004). D529F, S573E, and R555K mutations of human wild-type
NBD1 were expressed and purified as previously described (Thibodeau
et al., 2005). Temperature melts were performed at 2 mM ATP (Hoelen
et al., 2010).
DF508 NBD1 Crystallization and Structure Determination
Crystals of murine CFTR NBD1 DF508 were grown using the vapor-diffusion
method by mixing 1 ml of 10 mg/ml of the murine DF508 NBD1 protein with
1 ml of the well solution (containing 3.5–4 M sodium acetate, pH 7.5) (Lewis
et al., 2004; Thibodeau et al., 2005). Crystals used for data collection were
flash-cooled by suspending in a nylon loop directly out of their mother liquor
and then plunging into liquid propane. X-ray diffraction data were acquired
at beamline 19-ID at the Structural Biology Center of the Advanced Photon
Source at Argonne National Laboratories. Statistical details of the final model
are found in Table S1.
Homology Model of CFTR
Murine NBD1 or DF508 (PDB 1R0W or 3SI7) and human NBD2 (PDB 3GD7)
were docked onto the Sav1866 structure (PDB 2HYD) (Dawson and Locher,
2007; Lewis et al., 2004). A set of sequences containing the ICL4 segments
of CFTR proteins and Sav1866 ICL2 was used to generate an alignment
using the JalView ClustalW function (Clamp et al., 2004; Waterhouse et al.,
2009). On the WT or DF508 CFTR models, F508K, R1070, R1070W residues
were modeled using the PyMOL (Schrodinger, 2010) mutagenesis function
(Figures 1B, 2B, rightmost panel, 5, 6, and S1). Contact distances between
CFTR ICL1 and ICL4 residues and murine WT or DF508 NBD1 residues
were calculated via a Perl script using the atomic coordinates from the
models.
CFTR Function
The whole-cell patch-clamp technique was used to measure Cl current as
previously described (Wang et al., 2006). Briefly, whole-cell conductance
responses were measured in response to 10 mM forskolin + 100 mM IBMX
and then 10 mM Inhibitor-172 (Inh-172). Current recording and analysis was
performed with pClamp 9.2 software and analyzed with Origin 8 software.
Transepithelial conductance (Gt) measurements across monolayers of tran-
siently transfected FRT cells were performed using an EVOM2 Epithelial
Voltohmmeter with a STX100 electrode (World Precision Instruments) at
37C. Gt was measured 10 min after treatment with 10 mM Forskolin +
100 mM IBMX and 5 min after 20 mM Inh-172.172 Cell 148, 164–174, January 20, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
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